Correlation Between Inhibikase Therapeutics and Compugen

Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Compugen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Compugen into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibikase Therapeutics and Compugen, you can compare the effects of market volatilities on Inhibikase Therapeutics and Compugen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Compugen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Compugen.

Diversification Opportunities for Inhibikase Therapeutics and Compugen

-0.57

Correlation Coefficient

Inhibikase Therapeutics  Compugen

Excellent diversification

The 3 months correlation between Inhibikase and Compugen is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Compugen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Compugen and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Compugen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Compugen has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Compugen go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and Compugen

Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 2.2 times more return on investment than Compugen. However, Inhibikase Therapeutics is 2.2 times more volatile than Compugen. It trades about 0.25 of its potential returns per unit of risk. Compugen is currently generating about -0.08 per unit of risk. If you would invest  120.00  in Inhibikase Therapeutics on September 12, 2024 and sell it today you would earn a total of  200.00  from holding Inhibikase Therapeutics or generate 166.67% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Inhibikase Therapeutics  vs.  Compugen

Inhibikase Therapeutics

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Compugen

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Compugen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Inhibikase Therapeutics and Compugen

The main advantage of trading using opposite Inhibikase Therapeutics and Compugen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Compugen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will offset losses from the drop in Compugen's long position.

The idea behind Inhibikase Therapeutics and Compugen pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.